10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel [Yahoo! Finance]
10x Genomics, Inc. (TXG)
Last 10x genomics, inc. earnings: 2/18 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue types PLEASANTON, Calif. March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications. These new products expand the breadth of the Xenium single cell spatial analysis menu. "We built Xenium to be the best performing platform for in situ analysis, not only at launch, but for the long term," said Michael Schnall-Levin , Founding Scientist and Chief Technology Officer at 10x Genomics. "These new products are a testament to how we listen closely to our customers to build products that are most responsive to their needs. We have several more launches planned for Xenium this year, as we continue to innovate, enhance and expand our menu of high-performing Xenium assays
Show less
Read more
Impact Snapshot
Event Time:
TXG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TXG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TXG alerts
High impacting 10x Genomics, Inc. news events
Weekly update
A roundup of the hottest topics
TXG
News
- 10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
- 10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $60.00 to $55.00. They now have a "buy" rating on the stock.MarketBeat
- Vizgen Issued a New US Patent for Its MERFISH Technology [Yahoo! Finance]Yahoo! Finance
- 10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024PR Newswire
- 10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Barclays PLC from $55.00 to $45.00. They now have an "overweight" rating on the stock.MarketBeat
TXG
Earnings
- 2/15/24 - Miss
TXG
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- 4/12/24 - Form PRE
- TXG's page on the SEC website